SymBio Pharmaceuticals Limited [4582.T]
TOKYO, May 12 (Pulse News Wire) – SymBio Pharmaceuticals Limited (4582.T) extended its cooperative research agreement (CRADA) with the National Institute of Allergy and Infectious Diseases (NIAID) of the US National Institutes of Health (NIH) for three more years. The extension focuses on developing treatments for Epstein-Barr virus (EBV)-related lymphoproliferative disorders (LPD) using Brincidofovir (BCV).
Under the renewed CRADA, which now runs until April 2029, SymBio and NIAID aim to validate BCV's therapeutic effects through animal models and non-clinical trials. CEO Fumiki Yoshida commented, “This collaboration advances our efforts to develop effective treatments for LPDs and EBV-related diseases, conditions with limited treatment options.” The company noted that the contract renewal would not impact its fiscal year ending December 2026 consolidated performance.
Additionally, SymBio continues to focus on three key therapeutic areas for BCV development: post-hematopoietic stem cell transplantation viral infections, blood cancers/solid tumors, and neurodegenerative diseases.
🟢 Confidence: High AI-translated content.